Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed malignant neoplasm * Not amenable to standard therapy or has failed existing first- and second-line therapies * Tumor positive for somatostatin receptors by OctreoScan within the past 4 weeks * At least 1 measurable lesion * Lesions that have been previously irradiated must demonstrate progression since radiation * At least 1 measurable somatostatin receptor-positive lesion that has not been irradiated within the past 4 weeks AND has not had full craniospinal radiation within the past 3 months * Bone marrow with at least 40% cellularity OR at least 20% cellularity with one million CD34+ stem cells/kg stored * No diffuse bone marrow involvement by OctreoScan scintigraphy PATIENT CHARACTERISTICS: Age * 2 to 25 Performance status * COG 0-2 OR * Karnofsky 60-100% OR * Lansky 60-100% Life expectancy * 2-12 months Hematopoietic * See Disease Characteristics * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic * Bilirubin less than 1.5 times normal * AST and ALT less than 2.5 times upper limit of normal Renal * Creatinine no greater than 1 mg/dL (children less than 5 years of age) * Creatinine less than 1.2 mg/dL (children 5 to 10 years of age) * Creatinine less than 1.7 mg/dL (children over 10 years of age) AND * Glomerular filtration rate at least 80 mL/min/m\^2 Cardiovascular * Shortening fraction at least 28% by echocardiogram * Ejection fraction at least 50% by bi-plane method of echocardiogram * No prior congestive heart failure unless ejection fraction at least 40% * No unstable angina pectoris * No cardiac arrhythmia * No symptomatic congestive heart failure Other * No other concurrent malignancy * No other significant uncontrolled medical, psychiatric, or surgical condition that would preclude study compliance * No antibodies to yttrium Y 90-DOTA-tyr3-octreotide or octreotide * No prior allergic reactions to compounds of similar chemical or biologic composition to yttrium Y 90-DOTA-tyr3-octreotide * No ongoing or active infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy * More than 28 days since prior long-acting somatostatin analogues * No concurrent somatostatin analogues 12 hours before or 12 hours after study drug administration * Concurrent hormonal therapy (other than somatostatin analogue) allowed provided patient received hormonal therapy for at least 2 months and has stable disease or progressive disease Radiotherapy * See Disease Characteristics * At least 4 weeks since prior radiotherapy * No prior radiotherapy to 25% or more of bone marrow * No prior external beam radiotherapy to both kidneys (scatter doses of less than 500 cGy to a single kidney or radiation to less than 50% of a single kidney is allowed) Surgery * At least 4 weeks since prior surgery Other * Recovered from prior therapy * At least 4 weeks since prior investigational drugs * No other concurrent approved or investigational anti-neoplastic therapies except for bisphosphonates * No concurrent combination antiretroviral therapy for HIV-positive patients